Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni plus Ribavirin for Prevention of HCC Recurrence in HCV Patients
NCT02959359Phase 4Withdrawn
- Sponsor
- Taipei Veterans General Hospital
- Start
- Nov 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of ledipasvir in hepatitis C (HCV), sponsored by Taipei Veterans General Hospital. Primary endpoint: Annual recurrence-free survival at 5 years. Planned start Nov 2016; status: withdrawn.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02959359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959359.